Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-PD-1 Antibody Combined With Chemotherapy as First-line Treatment of Serum AFP-elevated Gastric or Gastroesophageal Junction Adenocarcinoma: a Single-arm, Multicenter Phase II Study

NCT04098796 is registered in ClinicalTrials.gov with China Medical University, China as lead sponsor.

NCT NCT04098796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04098796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-PD-1 Antibody Combined With Chemotherapy as First-line Treatment of Serum AFP-elevated Gastric or Gastroesophageal Junction Adenocarcinoma: a Single-arm, Multicenter Phase II Study
Lead sponsor
China Medical University, China
Phase
Phase 2
Overall status
Unknown status
Start date
October 1, 2019
Completion date
September 30, 2021
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

afp, gastric or gastroesophageal junction adenocarcinoma